Product Information
Registration Status: ActiveSIN08976P
CRIXIVAN CAPSULE 200mg is approved to be sold in Singapore with effective from 1996-03-06. It is marketed by MSD PHARMA (SINGAPORE) PTE LTD, with the registration number of SIN08976P.
This product contains Indinavir 200mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by Merck Sharp & Dohme Corp. in UNITED STATES.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Indication
Indinavir is an antiretroviral drug for the treatment of HIV infection.
Mechanism of Action
Indinavir inhibits the HIV viral protease enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Pharmacokinetics
- Absorption
- Rapidly absorbed
- Distribution
- Metabolism
- Hepatic. Seven metabolites have been identified, one glucuronide conjugate and six oxidative metabolites. In vitro studies indicate that cytochrome P-450 3A4 (CYP3A4) is the major enzyme responsible for formation of the oxidative metabolites.
- Elimination
Toxicity
Symptoms of overdose include myocardial infarction and angina pectoris.
Active Ingredient/Synonyms
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide | Indinavir anhydrous | Indinavir |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.